Claspin and Cancer: Where Are We Now?
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Diana Azenha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Farmácia da Universidade de Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Hauptthemen laut MEDLINE: Neoplasms, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer cells arise from the cumulative acquisition of genetic and epigenetic alterations that affect vital cellular functions. Genomic instability results from deficiencies in protective mechanisms, such as cell cycle checkpoints, DNA replication control, or DNA repair. Claspin integrates a group of crucial proteins that maintain genome integrity. It participates in key cellular events such as DNA damage checkpoint activation, DNA replication, replication stress responses, DNA repair, epigenetic memory, and apoptosis. Given its crucial functions, a role for Claspin in cancer is not a surprise. Indeed, there is a considerable body of evidence linking Claspin deregulation with cancer. For instance, over-expression of Claspin and Tim promoted the survival of cancer cells by enabling adaptation to oncogene-induced replication stress. In addition, Claspin gene (CLSPN) mutations that affect checkpoint regulation have been identified in cancer patients, suggesting that they may contribute to cancer development. Changes in Claspin expression levels may be used as a prognostic marker in several types of cancer. Finally, several therapy-resistance signaling pathways seem to converge onto Claspin’s stabilization, turning Claspin into an attractive target for chemo- and radio-sensitization. In this review, we will focus on the role of Claspin in cancer and ways in which Claspin can be exploited in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Farmácia da Universidade de Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
- Innovative Therapies: Tumor Microenvironment and Targeted Therapies, Center for Neuroscience and Cell Biology, Faculdade de Medicina, University of Coimbra, Rua Larga, Pólo I, 1º andar, 3004-504 Coimbra, Portugal.
- Molecular Pathology Laboratory, Portuguese Institute for Oncology at Coimbra Francisco Gentil, EPE, Av. Bissaya Barreto, 98, Apartado 2005, 3000-651 Coimbra, Portugal.
ORCID-Profile: Diana Azenha
Zitieren
APA
Azenha, D., & Martins, T. C. (2025). Claspin and Cancer: Where Are We Now?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188828
Vancouver
Azenha D, Martins TC. Claspin and Cancer: Where Are We Now?. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188828
BibTeX
@article{Azenha2025,
author = {Azenha, Diana and Martins, Teresa C},
title = {Claspin and Cancer: Where Are We Now?},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188828}
}
EUVIMED